Next Article in Journal
The Efficacy and Safety of EUS-Guided Gallbladder Drainage as a Bridge to Surgery for Patients with Acute Cholecystitis
Previous Article in Journal
Healthcare Resources Utilization throughout the Last Year of Life after Acute Myocardial Infarction
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 12
Issue 8
10.3390/jcm12082775
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Association between Sex-Related ALOX5 Gene Polymorphisms and Lung Atopy Risk

by
Davida Mirra
1,†,
Renata Esposito
1,†,
Giuseppe Spaziano
1,*,
Concetta Rafaniello
2,3,*,
Pasquale Iovino
1,
Erika Cione
4,
Luca Gallelli
5 and
Bruno D’Agostino
1
1
Department of Environmental Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy
2
Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, 80138 Naples, Italy
3
Department of Experimental Medicine, Section of Pharmacology “L. Donatelli”, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
4
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy
5
Clinical Pharmacology and Pharmacovigilance Unit, Department of Health Sciences, Mater Domini Hospital, University of Catanzaro, 88100 Catanzaro, Italy
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Clin. Med. 2023, 12(8), 2775; https://doi.org/10.3390/jcm12082775
Submission received: 16 December 2022 / Revised: 29 March 2023 / Accepted: 6 April 2023 / Published: 8 April 2023
(This article belongs to the Section Immunology)
Browse Figures
Versions Notes

Abstract

:
Atopy is an exaggerated IgE-mediated immune response to foreign antigens in which metabolic abnormalities of the leukotrienes (LTs) pathway play a crucial role. Recent studies have described sex as a key variable in LT biosynthesis, partly explaining why treatment with anti-LT drugs in atopic subjects leads to better control of symptoms in women. In addition, variability in LT production is often associated with single nucleotide polymorphisms (SNPs) in the arachidonate 5-lipoxygenase (ALOX5) gene, which encodes the leukotriene-synthesizing enzyme machinery, 5-lipoxygenase (5-LO). This study aimed to investigate whether two SNPs of ALOX5 are implicated in sex differences in allergic diseases in a prospective cohort of 150 age- and sex-matched atopic and healthy subjects. Rs2029253 and rs2115819 were genotyped using allele-specific RT-PCR, and serum levels of 5-LO and LTB4 were measured by ELISA. Both polymorphisms are significantly more common in women than in men, and their influences on LT production vary as a function of sex, leading to a decrease in men’s and an increase in women’s serum levels of 5-LO and LTB4. These data represent a new resource for understanding sex-related differences in lung inflammatory diseases, partly explaining why women are more likely to develop allergic disorders than men.

1. Introduction

Pharmacogenomics have become essential in the study of allergic respiratory diseases, as they show how polymorphisms can affect lung function [1,2,3]. Single nucleotide polymorphisms (SNPs) of the leukotrienes (LTs) pathway represent a risk factor for allergic diseases, influencing the severity of symptoms, the course of disease, and the response to drug treatment [4,5]. Indeed, arachidonate 5-lipoxygenase (ALOX5) gene, encoding for the leukotriene-synthesizing enzyme machinery 5-lipoxygenase (5-LO), is highly polymorphic and often results in the variable production of cysteinyl leukotrienes (CysLTs) and leukotriene B4 (LTB4) [6,7,8]. These inflammatory lipid mediators, produced by arachidonic acid oxidative metabolism via multistep enzymatic reactions, show their biological effects by binding to metabotropic receptors (CysLT 1-CysLT2 or BLT1-BLT2) [9,10]. In particular, LTB4 is a potent chemotactic agent and plays a key role in many inflammatory diseases, including asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, chronic obstructive pulmonary disease, and pulmonary arterial hypertension, which are characterized by dysregulated fatty acid metabolism [11,12,13,14,15,16,17,18]. Understanding the mechanism responsible for this metabolic abnormality has led to the identification of altered expression of enzymes involved in LT biogenesis [19]. Several mutations occur within the ALOX5 promoter region and are associated with airway hyperresponsiveness and asthma severity [20,21]. Indeed, the promoter region lacks the typical TATA or CCAT boxes but contains eight GC boxes, five of which are arranged in tandem (GGGCGG) and can bind to the SP1 and EGR-1 transcription factors [22]. The Sp1 repeat polymorphism is an important marker for lung inflammatory diseases and consists of the addition of zinc finger (Sp1/Egr-1) binding sites in the region upstream of the ATG translation start site [23,24,25,26]. Moreover, rs2029253 and rs2115819, two intronic variants in the ALOX5 gene, which consists of an A > G and an A > T substitution in the two alleles, respectively, have been associated with modified transcription activity (altered expression of ALOX5) and, consequently, with a different activity of 5-LO [27,28]. Nevertheless, reported data are still conflicting, with some authors associating them with better responses to anti-LTs and others associating them with reduced responses [29,30]. Montelukast, a cysLTR1 antagonist, is widely used for asthma treatment as an alternative to or in association with Inhaled Corticosteroids (ICS) in steps 3 or 4 of allergic rhinitis treatment, and in the prophylaxis of exercise-induced asthma [31]. Although several papers described the efficacy and safety of montelukast in both asthmatic adults and children, there were significant percentages of non-responders (35 to 78%) [32,33]. In our previous study, we reported that treatment with montelukast in women decreases inflammation, enhances the control of symptoms and management of lung function and results in lower levels of inflammation compared to men [34]. Indeed, recent studies have described sex as a key variable in LT biosynthesis, partly explaining why women are more likely to develop asthma than men and the different responses to anti-LT drugs [35,36]. This variability is often associated with the above-mentioned polymorphisms or with those present in the gene encoding cysLTR1 [30,37,38]. Several studies have reported that polymorphisms in the ALOX5 gene influence LT production; however, no study has analyzed whether this influence is different between men and women. Therefore, the aim of this study was to assess whether two genetic variations of the ALOX5 gene, rs2029253 and rs2115819, are implicated in the sex difference in allergic diseases in a well-characterized patient cohort of both atopic and healthy subjects.

2. Materials and Methods

2.1. Population

Herein, we carried out an observational clinical study on 150 age- and sex-matched subjects with atopy and healthy controls enrolled at the “Mater Domini” Hospital in Catanzaro, Italy. Based on their clinical characteristics, all patients underwent routine venous blood collection in accordance to normal clinical practice. This study belongs to a clinical trial recorded in clinicaltrials.gov (NCT04567212) and was approved by the local Ethics Committee “Calabria Centro”. This work was performed following the Institutional Review Board/Human Subjects Research Committee requirements and the Declaration of Helsinki and the Guidelines for Good Clinical Practice criteria. Prior of the beginning of the study, all patients or legal guardians signed the informed consent.
Inclusion criteria: patients with a diagnosis of atopy in agreement with international guidelines, both sexes, ages between 6 and 85 years.
Exclusion criteria: Subjects with severe asthma or with mixed asthma (asthma and chronic obstructive pulmonary disease) or with active pulmonary infections or immune disorders were not enrolled. In addition, we excluded those who did not sign the informed consent.

2.2. Data Collection and Genomic DNA Extraction

Clinical features and treatment data were obtained during enrollment and examined by a team of physicians. EDTA-anticoagulated venous samples were taken after a 12 h overnight fast and analyzed within 2 h of collection. A first centrifugation at 1800× g for 10 min at room temperature was performed to gather serum, which was further centrifuged at 1200× g for 20 min at 10 °C to completely remove cell debris. Finally, serum samples were aliquoted to prevent freeze–thaw cycles and stored at −80 °C until DNA extraction. Genomic DNA were extracted from serum samples from all participants using a salting-out method [39]. Briefly, SDS (10%) and Proteinase K (1 mg/mL) were added to the samples for cell lysis and protein digestion, and proteins were precipitated using NaCl-saturated distilled water. Finally, the samples were centrifuged, and DNA precipitation was performed using 2-propanol. The extracted DNA were quantified by qubit DNA DS Assay Kit, which ensures simple and accurate quantification of DNA using the Qubit 4 Fluorometer; 1 µL of each sample was quantified.

2.3. SNPs Genotyping and Serum 5-LO and LTB4 ELISA Quantification

Target SNPs, rs2029253 (ALOX5) and rs2115819 (ALOX5) were genotyped via the TaqMan SNP assay (Applied Biosystems, Waltham, MA, USA) and DNA amplification, based on the fluorescence intensity of a fluorogenic probe specific to the target sequence, was assessed by an Applied Biosystems Quanto Studio 5 Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). Thermocycling conditions were as follows: an initial pre-read step at 60 °C for 30 s; a denaturation step at 95 °C for 5 min; 40 cycles of denaturation at 95 °C for 15 s; annealing at 60 °C for 1 min; and a post-read step at 60 °C for 30 s. 5-LO enzyme and LTB4 levels were measured in a subgroup of subjects by using ELISA kits and all samples were analyzed in duplicate. Rs2029253 were analyzed in: 4 M (2 healthy and 2 atopic) and 4 W (2 healthy and 2 atopic) without mutation; 4 M (all healthy) and 6 W (3 healthy and 3 atopic) carrying homozygous wild-type allele; 3 M (all healthy) and 4 W (3 healthy and 1 atopic) carrying homozygous variant allele; and 6 M (3 healthy and 3 atopic) and 4 W (2 healthy and 2 atopic) carrying heterozygous alleles. Rs2115819 were analyzed in: 4 M (2 healthy and 2 atopic) and 4 W (2 healthy and 2 atopic) without mutation; 6 M (all healthy) and 8 W (4 healthy and 4 atopic) carrying homozygous wild-type allele; 6 M (all healthy) and 6 W (2 healthy and 4 atopic) carrying homozygous variant allele; and 7 M (4 healthy and 3 atopic) and 6 W (3 healthy and 3 atopic) carrying heterozygous alleles. Briefly, assay samples and buffers were incubated with HRP conjugates in pre-coated plates for one hour. After the incubation, the wells were decanted, rinsed five times and incubated with substrates for the HRP enzyme. The product of the reaction between enzyme and substrate developed a blue complex. Finally, to stop the reaction a stop solution was added, which turned the solution yellow. The intensity of color was measured in a microplate spectrometer reader at 450 nm, and a standard curve was plotted correlating the color intensity (O.D.) to the standards concentration. The 5-LO and LTB4 concentrations in each sample were interpolated from this standard curve.

2.4. Statistical Analysis

Clinical characteristics and SNP frequency data were expressed as mean ± standard deviation (SD) while 5-LO and LTB4 serum levels were expressed as standard error mean (SEM). We used nominal (sex, comorbidity, and treatment) and categorical variables (age or weight) and correlations between clinical characteristics were calculated using the one-way ANOVA followed by the Tukey Multiple Comparison Test. The two-way ANOVA test followed by the Tukey Multiple Comparison Test were chosen to evaluate the differences between the groups. Correlations between serum 5-LO and LTB4 levels were calculated using the Spearman correlation test. Statistical analyses were performed using GraphPad software (version 8.0) (GraphPad Software, San Diego, CA, USA). Differences were considered statistically significant at p < 0.05.

3. Results

3.1. Clinical Characteristics

Clinical characteristics and pharmacological therapy of atopic subjects and control participants are described in Table 1.

3.2. ALOX5 Mutations Frequencies in Men and Women

ALOX5 rs2029253 and rs2115819 frequencies were assessed according to sex in both atopic and healthy subjects (Table 2 and Table 3, respectively). In the total population, there were significantly more Women (W) carrying rs2029253 than Men (M) (p < 0.01), whereas there was no difference found regarding rs2115819. Moreover, a sub-analysis according to disease status revealed that both atopic and healthy W carrying rs2029253 were significantly more frequent than M (p < 0.05 and p < 0.01, respectively), as shown in Table 2. A similar trend was reported for rs2115819 in atopic subjects, which was more frequent in W compared to M; while in healthy subjects, M carrying the mutation were significantly more common compared to W (p < 0.0001 and p < 0.001, respectively), as shown in Table 3.
Both healthy and atopic populations were stratified by allele and genotype into four subgroups for each SNP: (1) total subjects with mutations; (2) subjects with homozygous wild-type allele (A > T in allele 1, the most frequently reported allele in the population); (3) subjects with homozygous variant allele (A > T in allele 2, the least frequently reported allele in the population); and (4) subjects with heterozygous allele (A > T in both alleles). Healthy W with rs2029253 homozygous wild-type and heterozygous alleles were significantly more frequent (p < 0.0001, and p < 0.001, respectively), whereas the homozygous variant allele was more frequent in M (p < 0.0001) (Table 4A). Among atopic subjects, rs2029253 homozygous wild-type and variant allele frequencies were significantly higher in W (p < 0.0001, and p < 0.0001, respectively), whereas the homozygous variant allele was more frequent in M (p < 0.0001) (Table 4B).
The genotype and allele frequency of ALOX5 rs2115819 showed opposite trends in healthy and atopic populations. Indeed, healthy M carrying rs2115819 homozygous wild-type and variant alleles were significantly more frequent (p < 0.001 and p < 0.0001, respectively) (Table 5A), whereas the same alleles were more frequent in atopic W (p < 0.0001, respectively) (Table 5B). Conversely, heterozygous alleles were more frequent in healthy W and atopic M (p < 0.0001, respectively) (Table 5A,B).

3.3. 5-LO Serum Levels According to Genotype ALOX5 rs2029253 and rs2115819 Polymorphisms

Serum levels of 5-LO and LTB4 were assessed in both M and W, mutated and unmutated, and were stratified by alleles. M without mutations showed higher levels of serum 5-LO compared to subjects presenting the rs2029253 polymorphism. In particular, M carrying the homozygous wild-type allele had the lowest levels of serum 5-LO (p < 0.05) (Figure 1A). Conversely W carrying the rs2029253 polymorphism, had a higher level of circulating 5-LO, specifically, those with the homozygous variant allele (p < 0.05) (Figure 1A). Like the rs2029253 mutation, M without mutations showed higher levels of serum 5-LO compared to subjects presenting the rs2115819 polymorphism, particularly compared to those carrying the homozygous variant allele (p < 0.001) (Figure 1B). In contrast, there were no significant differences between the serum 5-LO levels of mutated and non-mutated W (Figure 1B).

3.4. LTB4 Serum Levels According to Genotype ALOX5 rs2029253 and rs2115819 Polymorphisms

The serum LTB4 levels showed a trend similar to the 5-LO serum levels. Indeed, M without mutations showed higher levels of serum LTB4 compared to subjects presenting the rs2029253 polymorphism, except for the heterozygous (Figure 2A). Conversely, W with the ALOX5 rs2029253 polymorphism showed significantly higher levels of LTB4, specifically, those carrying the homozygous wild-type allele (p < 0.01) (Figure 2A).
M without mutations showed higher levels of serum LTB4 compared to subjects presenting the rs2115819 polymorphism, except for the heterozygous (Figure 2B). In contrast, W with the ALOX5 rs2115819 polymorphism showed higher levels of LTB4, although it only reached statistical significance in subjects carrying the homozygous wild-type allele (p < 0.01) (Figure 2B).

3.5. Correlation between LTB4 and 5-LO Serum Levels

When we correlated LTB4 and 5-LO serum levels in M patients with genotype ALOX5 rs2029253, we did not find a significant association (Figure 3A). Instead, the overall LTB4 serum levels were strongly directly correlated with circulating 5-LO levels in W (p < 0.01), indicating a stronger association in W carrying homozygous variant allele and homozygous wild type allele (Figure 3B).
Among M patients, there was no significant association between LTB4 and 5-LO serum levels according to the ALOX5 rs2115819 polymorphism (Figure 4A). Instead, we found a strong and direct correlation in W (p < 0.0001), particularly in those carrying the homozygous variant allele and homozygous wild-type allele (Figure 4B).

4. Discussion

For the first time, the present study identifies the relationship between ALOX5 genetic variations and sex-related differences in leukotriene production in a gender-balanced cohort of atopic and healthy subjects. Atopy is an exaggerated IgE-mediated immune response to foreign antigens that makes the immune system more sensitive to common allergic triggers [40]. It is a heterogeneous disease and can be related to other diseases [41,42,43,44,45,46,47,48]. Atopic disorders include various lung inflammatory diseases (e.g., allergic asthma and IgE-mediated components of allergic aspergillosis), allergic rhinitis, conjunctivitis, and atopic dermatitis, in which metabolic abnormalities of the leukotriene pathway play a crucial role [11,12,13,14,15,16,17,18]. The coding gene for the leukotriene-synthesizing enzyme machinery, ALOX5, is highly polymorphic and often results in the variable production of CysLTs (LTC4, LTD4, and LTE4) and LTB4 [6,8]. This variability is often associated with a significantly altered response to montelukast, a cysLTR1 antagonist widely used for the treatment of asthma or allergic rhinitis [30,31,37,38]. Recent studies have described sex as a key variable in LT biosynthesis, partly explaining why women are more likely to develop allergic diseases than men and the differences in response to anti-LT drugs [35,36]. Although several studies have reported that SNPs in ALOX5 gene could influence LT production, no study has analyzed them in men and woman distinctly. Therefore, we assessed the frequencies of two SNPs in ALOX5 gene and correlated them with serum 5-LO and LTB4 levels in men and women. We showed that ALOX5 rs2029253 is significantly more common in both atopic and healthy women than in men, while rs2115819 is significantly more common only in atopic W. Furthermore, their influence on LT production varies as a function of gender. Genetic and epigenetic regulation of inflammation are important biological risk factors involved in the development of many diseases, including atopy [49,50]. Rs2029253 and rs2115819 are two intronic variants in the ALOX5 gene, which consist of an A> G and a A >T substitution in the two alleles, respectively, and have been associated with abnormalities in leukotriene production [27,28]. Nevertheless, reported data are still conflicting, with some authors associating them with better responses to anti-LTs and others associating them with reduced responses. First, Tantsira et al. showed an association between the rs2029253 variant and response to zileuton, but not montelukast. In addition, the same authors reported that ALOX5 rs2115819 was associated with decrements in response to both zileuton and montelukast therapy [29]. Then, Lima et al. genotyped 28 SNPs in five leukotriene pathway genes associating ALOX5 rs2115819 with changes in FEV1 and a reduction in exacerbations of asthma in patients treated with montelukast for 6 months [30]. As studies of ALOX5 polymorphisms have mainly focused on the association with anti-LT drugs, the failure to assess the frequency and effect of these mutations separately between men and women may have resulted in variable data. Our study partly explains this mixture of data in the literature, showing that the genotypes produced from the two SNPs in ALOX5 gene vary as a function of gender and are more likely associated with the female rather than the male population. In addition to changes in SNP frequency, we also assessed 5-LO and LTB4 serum levels directly. Interestingly, despite a different distribution of the two SNPs, they shared a similar influence on LT production, with opposite results in men and women leading to decreased and increased 5-LO and LTB4 serum levels, respectively. Moreover, we found that LTB4 serum levels were strongly and directly correlated with circulating 5-LO levels only in women, particularly in those carrying homozygous variant allele and homozygous wild type allele. In accordance with studies reporting a higher rate of allergic diseases in woman, our data suggest an overall increase in LT production in the female population carrying these mutations and a higher susceptibility to allergic disorders [51,52]. It is tempting to ascribe the gender differences in the effects of ALOX5 polymorphisms on LT biosynthesis to the known effects of sex hormones on the expression of genes involved in regulating innate immunity. To date, several clinical and preclinical studies employing animal models of allergic asthma and atopy have described sex differences and the impacts of sex hormones on the of LT biosynthesis in several cells and tissues. Changes in LT production may take place at different levels involving biosynthetic enzyme expression, availability of arachidonic acid, modulation of phosphorylation or subcellular distribution of enzymes [53]. Indeed, there are accumulating evidence indicating that androgens could lower LT levels in vitro and in vivo [54,55,56,57]. Pergola et al. demonstrated that human monocytes derived from females have greater 5-LO product formation than those derived from males and showed that in vitro stimulation with testosterone metabolites of female-derived monocytes suppressed 5-LO products biosynthesis [58]. In accordance with this evidence, in our previous study, we showed that montelukast enhances symptom control and management of lung function and decreases inflammation more in women than in men [34]. Therefore, the establishment of the LT pathway and its functions, that could be modulated by genetically controlled differences in the human ALOX5 gene, may differ between male and female subjects. Previous studies have investigated and reported the association between specific disease-related SNPs and sex. Volf et al. reported that the effects of the 5-HTTLPR polymorphism on brain electrical activity differed as a function of sex, implicating sex-related differences in affective states, emotions, and cognition [59]. In addition, Bi et al. showed that the influence of IL-6 gene polymorphisms on IL-6 biosynthesis and susceptibility to cerebral palsy development is related to sex and gestational age [60]. Therefore, we hypothesize that genetic variation may enhance or weaken the LT-mediated inflammation involved in the pathogenetic process of atopy in a sex-related manner or influence the relationship between genetic factors and the environment.

5. Conclusions

To our knowledge, this study gives the first evidence that 5-LO and LTB4 participate in the pathogenesis of atopy in a sex-related manner, and that ALOX5 gene polymorphisms are risk markers for the development of atopy in female patients. Our data, even if preliminary, represent a new resource for understanding sex-related differences in lung inflammatory disease, partly explaining why women are more likely to develop allergic disorders than men. However, we cannot exclude the potential problem of small sample size after genotyping. For this reason, we could not stratify the subjects according to disease status and 5-LO or LTB4 levels. Nevertheless, given the low frequencies of these mutations, our findings could be clinically relevant and lead to future studies involving larger populations. The current findings suggest that it may be worthwhile for future research to examine the impacts of gene and sex interactions on lung function. Therefore, additional investigations in larger cohorts are needed to clarify the role of genetic variation in sex variability in anti-LT drug responses and to establish a gender-tailored therapeutic approach for the disease.

Author Contributions

Conceptualization, D.M., G.S., E.C., L.G. and B.D.; Data curation, G.S., C.R. and E.C.; Formal analysis, R.E. and E.C.; Funding acquisition, C.R.; Investigation, D.M., R.E. and E.C.; Methodology, D.M., R.E. and E.C.; Project administration, G.S., L.G. and B.D.; Resources, G.S.; Supervision, G.S., P.I., E.C., L.G. and B.D.; Validation, G.S.; Visualization, R.E., G.S. and P.I.; Writing—original draft, D.M.; Writing—review & editing, E.C. and B.D. All authors have read and agreed to the published version of the manuscript.

Funding

This research did not receive any external funding.

Institutional Review Board Statement

This study belongs to the clinical trial recorded in clinicaltrials.gov (NCT04567212) and was approved by the local Ethics Committee “Calabria Centro”. This work was carried out in conformance with the Institutional Review Board/Human Subjects Research Committee requirements and the Declaration of Helsinki and the Guidelines for Good Clinical Practice criteria.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Dr. Spaziano keeps the raw data and figures for each of the experiments performed. The data are available upon request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Hall, I.P.; Sayers, I. Pharmacogenetics and Asthma: False Hope or New Dawn? Eur. Respir. J. 2007, 29, 1239–1245. [Google Scholar] [CrossRef]
  2. Palmer, L.J.; Silverman, E.S.; Weiss, S.T.; Drazen, J.M. Pharmacogenetics of Asthma. Am. J. Respir. Crit. Care Med. 2002, 165, 861–866. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Hur, G.Y.; Broide, D.H. Genes and Pathways Regulating Decline in Lung Function and Airway Remodeling in Asthma. Allergy Asthma Immunol. Res. 2019, 11, 604. [Google Scholar] [CrossRef] [PubMed]
  4. Mougey, E.; Lang, J.E.; Allayee, H.; Teague, W.G.; Dozor, A.J.; Wise, R.A.; Lima, J.J. ALOX5 Polymorphism Associates with Increased Leukotriene Production and Reduced Lung Function and Asthma Control in Children with Poorly Controlled Asthma. Clin. Exp. Allergy 2013, 43, 512–520. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Duroudier, N.P.; Tulah, A.S.; Sayers, I. Leukotriene Pathway Genetics and Pharmacogenetics in Allergy. Allergy 2009, 64, 823–839. [Google Scholar] [CrossRef] [PubMed]
  6. Bizzintino, J.A.; Khoo, S.-K.; Zhang, G.; Martin, A.C.; Rueter, K.; Geelhoed, G.C.; Goldblatt, J.; Laing, I.A.; Le Souëf, P.N.; Hayden, C.M. Leukotriene Pathway Polymorphisms Are Associated with Altered Cysteinyl Leukotriene Production in Children with Acute Asthma. Prostaglandins Leukot. Essent. Fat. Acids 2009, 81, 9–15. [Google Scholar] [CrossRef]
  7. Thompson, M.D.; Capra, V.; Clunes, M.T.; Rovati, G.E.; Stankova, J.; Maj, M.C.; Duffy, D.A. Cysteinyl Leukotrienes Pathway Genes, Atopic Asthma and Drug Response: From Population Isolates to Large Genome-Wide Association Studies. Front. Pharmacol. 2016, 7, 299. [Google Scholar] [CrossRef] [Green Version]
  8. Funk, C.D.; Hoshiko, S.; Matsumoto, T.; Rdmark, O.; Samuelsson, B. Characterization of the Human 5-Lipoxygenase Gene. Proc. Natl. Acad. Sci. USA 1989, 86, 2587–2591. [Google Scholar] [CrossRef] [Green Version]
  9. Peters-Golden, M.; Henderson, W.R., Jr. Leukotrienes. N. Engl. J. Med. 2007, 357, 1841–1854. [Google Scholar] [CrossRef]
  10. Folco, G.; Murphy, R.C. Eicosanoid Transcellular Biosynthesis: From Cell-Cell Interactions to In Vivo Tissue Responses. Pharm. Rev. 2006, 58, 375–388. [Google Scholar] [CrossRef]
  11. Singh, R.K.; Tandon, R.; Dastidar, S.G.; Ray, A. A Review on Leukotrienes and Their Receptors with Reference to Asthma. J. Asthma 2013, 50, 922–931. [Google Scholar] [CrossRef]
  12. Gelfand, E.W. Importance of the Leukotriene B4-BLT1 and LTB4-BLT2 Pathways in Asthma. Semin. Immunol. 2017, 33, 44–51. [Google Scholar] [CrossRef] [PubMed]
  13. Holgate, S.T.; Peters-Golden, M.; Panettieri, R.A.; Henderson, W.R. Roles of Cysteinyl Leukotrienes in Airway Inflammation, Smooth Muscle Function, and Remodeling. J. Allergy Clin. Immunol. 2003, 111, S18–S36. [Google Scholar] [CrossRef] [PubMed]
  14. Schaible, A.M.; Filosa, R.; Temml, V.; Krauth, V.; Matteis, M.; Peduto, A.; Bruno, F.; Luderer, S.; Roviezzo, F.; Di Mola, A.; et al. Elucidation of the Molecular Mechanism and the Efficacy In Vivo of a Novel 1,4-Benzoquinone That Inhibits 5-Lipoxygenase: 5-Lipoxygenase Inhibition by a 1,4-Benzoquinone. Br. J. Pharmacol. 2014, 171, 2399–2412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Schaible, A.M.; Filosa, R.; Krauth, V.; Temml, V.; Pace, S.; Garscha, U.; Liening, S.; Weinigel, C.; Rummler, S.; Schieferdecker, S.; et al. The 5-Lipoxygenase Inhibitor RF-22c Potently Suppresses Leukotriene Biosynthesis in Cellulo and Blocks Bronchoconstriction and Inflammation In Vivo. Biochem. Pharmacol. 2016, 112, 60–71. [Google Scholar] [CrossRef]
  16. Liparulo, A.; Esposito, R.; Santonocito, D.; Muñoz-Ramírez, A.; Spaziano, G.; Bruno, F.; Xiao, J.; Puglia, C.; Filosa, R.; Berrino, L.; et al. Formulation and Characterization of Solid Lipid Nanoparticles Loading RF22-c, a Potent and Selective 5-LO Inhibitor, in a Monocrotaline-Induced Model of Pulmonary Hypertension. Front. Pharmacol. 2020, 11, 83. [Google Scholar] [CrossRef] [Green Version]
  17. Çobanoğlu, B.; Toskala, E.; Ural, A.; Cingi, C. Role of Leukotriene Antagonists and Antihistamines in the Treatment of Allergic Rhinitis. Curr. Allergy Asthma Rep. 2013, 13, 203–208. [Google Scholar] [CrossRef]
  18. Montuschi, P. Exhaled Leukotrienes and Prostaglandins in COPD. Thorax 2003, 58, 585–588. [Google Scholar] [CrossRef] [Green Version]
  19. Bleecker, E.; Ortega, V.; Meyers, D. Asthma Pharmacogenetics and the Development of Genetic Profiles for Personalized Medicine. PGPM 2015, 8, 9–22. [Google Scholar] [CrossRef] [Green Version]
  20. Horn, T.; Reddy Kakularam, K.; Anton, M.; Richter, C.; Reddanna, P.; Kuhn, H. Functional Characterization of Genetic Enzyme Variations in Human Lipoxygenases. Redox Biol. 2013, 1, 566–577. [Google Scholar] [CrossRef] [Green Version]
  21. Kalayci, O.; Birben, E.; Sackesen, C.; Keskin, O.; Tahan, F.; Wechsler, M.E.; Civelek, E.; Soyer, O.U.; Adalioglu, G.; Tuncer, A.; et al. ALOX5 Promoter Genotype, Asthma Severity and LTC4 Production by Eosinophils: ALOX5 Genotype Variants in Asthma. Allergy 2005, 61, 97–103. [Google Scholar] [CrossRef]
  22. Schlag, K.; Steinhilber, D.; Karas, M.; Sorg, B.L. Analysis of Proximal ALOX5 Promoter Binding Proteins by Quantitative Proteomics. FEBS J. 2020, 287, 4481–4499. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. In, K.H.; Asano, K.; Beier, D.; Grobholz, J.; Finn, P.W.; Silverman, E.K.; Silverman, E.S.; Collins, T.; Fischer, A.R.; Keith, T.P.; et al. Naturally Occurring Mutations in the Human 5-Lipoxygenase Gene Promoter That Modify Transcription Factor Binding and Reporter Gene Transcription. J. Clin. Investig. 1997, 99, 1130–1137. [Google Scholar] [CrossRef]
  24. Drazen, J.M.; Yandava, C.N.; Dubé, L.; Szczerback, N.; Hippensteel, R.; Pillari, A.; Israel, E.; Schork, N.; Silverman, E.S.; Katz, D.A.; et al. Pharmacogenetic Association between ALOX5 Promoter Genotype and the Response to Anti-Asthma Treatment. Nat. Genet. 1999, 22, 168–170. [Google Scholar] [CrossRef]
  25. Sayers, I.; Barton, S.; Rorke, S.; Sawyer, J.; Peng, Q.; Beghé, B.; Ye, S.; Keith, T.; Clough, J.B.; Holloway, J.W.; et al. Promoter Polymorphism in the 5-Lipoxygenase (ALOX5) and 5-Lipoxygenase-Activating Protein (ALOX5AP) Genes and Asthma Susceptibility in a Caucasian Population: ALOX5 and ALOX5AP Promoter Polymorphism. Clin. Exp. Allergy 2003, 33, 1103–1110. [Google Scholar] [CrossRef] [PubMed]
  26. Kim, S.-H.; Bae, J.-S.; Suh, C.-H.; Nahm, D.-H.; Holloway, J.W.; Park, H.-S. Polymorphism of Tandem Repeat in Promoter of 5-Lipoxygenase in ASA-Intolerant Asthma: A Positive Association with Airway Hyperresponsiveness. Allergy 2005, 60, 760–765. [Google Scholar] [CrossRef]
  27. Crosslin, D.R.; Shah, S.H.; Nelson, S.C.; Haynes, C.S.; Connelly, J.J.; Gadson, S.; Goldschmidt-Clermont, P.J.; Vance, J.M.; Rose, J.; Granger, C.B.; et al. Genetic Effects in the Leukotriene Biosynthesis Pathway and Association with Atherosclerosis. Hum. Genet. 2009, 125, 217–229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Geiger, E.V.; Doehring, A.; Kirchhof, A.; Lötsch, J. Functional Variants of the Human 5-Lipoxygenase Gene and Their Genetic Diagnosis. Prostaglandins Leukot. Essent. Fat. Acids 2009, 80, 255–262. [Google Scholar] [CrossRef]
  29. Tantisira, K.G.; Lima, J.; Sylvia, J.; Klanderman, B.; Weiss, S.T. 5-Lipoxygenase Pharmacogenetics in Asthma: Overlap with Cys-Leukotriene Receptor Antagonist Loci. Pharm. Genom. 2009, 19, 244–247. [Google Scholar] [CrossRef] [Green Version]
  30. Lima, J.J.; Zhang, S.; Grant, A.; Shao, L.; Tantisira, K.G.; Allayee, H.; Wang, J.; Sylvester, J.; Holbrook, J.; Wise, R.; et al. Influence of Leukotriene Pathway Polymorphisms on Response to Montelukast in Asthma. Am. J. Respir. Crit. Care Med. 2006, 173, 379–385. [Google Scholar] [CrossRef] [Green Version]
  31. Storms, W. Update on Montelukast and Its Role in the Treatment of Asthma, Allergic Rhinitis and Exercise-Induced Bronchoconstriction. Expert. Opin. Pharmacother. 2007, 8, 2173–2187. [Google Scholar] [CrossRef] [PubMed]
  32. Szefler, S.J.; Phillips, B.R.; Martinez, F.D.; Chinchilli, V.M.; Lemanske, R.F.; Strunk, R.C.; Zeiger, R.S.; Larsen, G.; Spahn, J.D.; Bacharier, L.B.; et al. Characterization of Within-Subject Responses to Fluticasone and Montelukast in Childhood Asthma. J. Allergy Clin. Immunol. 2005, 115, 233–242. [Google Scholar] [CrossRef] [PubMed]
  33. Israel, E.; Chervinsky, P.S.; Friedman, B.; van Bavel, J.; Skalky, C.S.; Ghannam, A.F.; Bird, S.R.; Edelman, J.M. Effects of Montelukast and Beclomethasone on Airway Function and Asthma Control. J. Allergy Clin. Immunol. 2002, 110, 847–854. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Esposito, R.; Spaziano, G.; Giannattasio, D.; Ferrigno, F.; Liparulo, A.; Rossi, A.; Roviezzo, F.; Sessa, M.; Falciani, M.; Berrino, L.; et al. Montelukast Improves Symptoms and Lung Function in Asthmatic Women Compared With Men. Front. Pharmacol. 2019, 10, 1094. [Google Scholar] [CrossRef] [PubMed]
  35. Rossi, A.; Roviezzo, F.; Sorrentino, R.; Riemma, M.A.; Cerqua, I.; Bilancia, R.; Spaziano, G.; Troisi, F.; Pace, S.; Pinto, A.; et al. Leukotriene-Mediated Sex Dimorphism in Murine Asthma-like Features during Allergen Sensitization. Pharmacol. Res. 2019, 139, 182–190. [Google Scholar] [CrossRef]
  36. Sessa, M.; Mascolo, A.; D’Agostino, B.; Casciotta, A.; D’Agostino, V.; Michele, F.D.; Polverino, M.; Spaziano, G.; Andersen, M.P.; Kragholm, K.; et al. Relationship Between Gender and the Effectiveness of Montelukast: An Italian/Danish Register-Based Retrospective Cohort Study. Front. Pharmacol. 2018, 9, 844. [Google Scholar] [CrossRef] [Green Version]
  37. Telleria, J.J.; Blanco-Quiros, A.; Varillas, D.; Armentia, A.; Fernandez-Carvajal, I.; Jesus Alonso, M.; Diez, I. ALOX5 Promoter Genotype and Response to Montelukast in Moderate Persistent Asthma. Respir. Med. 2008, 102, 857–861. [Google Scholar] [CrossRef]
  38. Klotsman, M.; York, T.P.; Pillai, S.G.; Vargas-Irwin, C.; Sharma, S.S.; van den Oord, E.J.C.G.; Anderson, W.H. Pharmacogenetics of the 5-Lipoxygenase Biosynthetic Pathway and Variable Clinical Response to Montelukast. Pharm. Genom. 2007, 17, 189–196. [Google Scholar] [CrossRef]
  39. Koshy, L.; Anju, A.L.; Harikrishnan, S.; Kutty, V.R.; Jissa, V.T.; Kurikesu, I.; Jayachandran, P.; Jayakumaran Nair, A.; Gangaprasad, A.; Nair, G.M.; et al. Evaluating Genomic DNA Extraction Methods from Human Whole Blood Using Endpoint and Real-Time PCR Assays. Mol. Biol. Rep. 2017, 44, 97–108. [Google Scholar] [CrossRef]
  40. Passalacqua, G.; Ciprandi, G. Allergy and the Lung. Clin. Exp. Immunol. 2008, 153 (Suppl. S1), 12–16. [Google Scholar] [CrossRef]
  41. Galli, S.J.; Tsai, M.; Piliponsky, A.M. The Development of Allergic Inflammation. Nature 2008, 454, 445–454. [Google Scholar] [CrossRef] [Green Version]
  42. Mirra, D.; Cione, E.; Spaziano, G.; Esposito, R.; Sorgenti, M.; Granato, E.; Cerqua, I.; Muraca, L.; Iovino, P.; Gallelli, L.; et al. Circulating MicroRNAs Expression Profile in Lung Inflammation: A Preliminary Study. JCM 2022, 11, 5446. [Google Scholar] [CrossRef] [PubMed]
  43. Mirra, D.; Spaziano, G.; Esposito, R.; Santonocito, D.; Filosa, R.; Roviezzo, F.; Malgieri, G.; D’Abrosca, G.; Iovino, P.; Gallelli, L.; et al. Formulation of Solid Lipid Nanoparticles Loaded with Nociceptin/Orphanin FQ (N/OFQ) and Characterization in a Murine Model of Airway Hyperresponsiveness. Pharmaceuticals 2022, 15, 1210. [Google Scholar] [CrossRef] [PubMed]
  44. Rouget, C.; Cui, Y.Y.; D’Agostino, B.; Faisy, C.; Naline, E.; Bardou, M.; Advenier, C. Nociceptin Inhibits Airway Microvascular Leakage Induced by HCl Intra-Oesophageal Instillation: Nociceptin and Gastro-Oesophageal Reflux. Br. J. Pharmacol. 2004, 141, 1077–1083. [Google Scholar] [CrossRef]
  45. D’Agostino, B.; Marrocco, G.; De Nardo, M.; Calò, G.; Guerrini, R.; Gallelli, L.; Advenier, C.; Rossi, F. Activation of the Nociceptin/Orphanin FQ Receptor Reduces Bronchoconstriction and Microvascular Leakage in a Rabbit Model of Gastroesophageal Reflux: N/OFQ Effects in the Airways in a GER Animal Model. Br. J. Pharmacol. 2005, 144, 813–820. [Google Scholar] [CrossRef]
  46. Gallelli, L.; D’Agostino, B.; Marrocco, G.; De Rosa, G.; Filippelli, W.; Rossi, F.; Advenier, C. Role of Tachykinins in the Bronchoconstriction Induced by HCl Intraesophageal Instillation in the Rabbit. Life Sci. 2003, 72, 1135–1142. [Google Scholar] [CrossRef]
  47. D’Agostino, B.; Advenier, C.; De Palma, R.; Gallelli, L.; Marrocco, G.; Abbate, G.F.; Rossi, F. The Involvement of Sensory Neuropeptides in Airway Hyper-Responsiveness in Rabbits Sensitized and Challenged to Parietaria Judaica: Sensory Neuropeptides in Airway Hyper-Responsiveness. Clin. Exp. Allergy 2002, 32, 472–479. [Google Scholar] [CrossRef]
  48. Cappetta, D.; De Angelis, A.; Spaziano, G.; Tartaglione, G.; Piegari, E.; Esposito, G.; Ciuffreda, L.P.; Liparulo, A.; Sgambato, M.; Russo, T.P.; et al. Lung Mesenchymal Stem Cells Ameliorate Elastase-Induced Damage in an Animal Model of Emphysema. Stem Cells Int. 2018, 2018, 9492038. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. Gupta, J.; Johansson, E.; Bernstein, J.A.; Chakraborty, R.; Khurana Hershey, G.K.; Rothenberg, M.E.; Mersha, T.B. Resolving the Etiology of Atopic Disorders by Using Genetic Analysis of Racial Ancestry. J. Allergy Clin. Immunol. 2016, 138, 676–699. [Google Scholar] [CrossRef] [Green Version]
  50. Perri, M.; Lucente, M.; Cannataro, R.; De Luca, I.F.; Gallelli, L.; Moro, G.; De Sarro, G.; Caroleo, M.C.; Cione, E. Variation in Immune-Related microRNAs Profile in Human Milk Amongst Lactating Women. MicroRNA 2018, 7, 107–114. [Google Scholar] [CrossRef]
  51. Uekert, S.; Akan, G.; Evans, M.; Li, Z.; Roberg, K.; Tisler, C.; Dasilva, D.; Anderson, E.; Gangnon, R.; Allen, D. Sex-Related Differences in Immune Development and the Expression of Atopy in Early Childhood. J. Allergy Clin. Immunol. 2006, 118, 1375–1381. [Google Scholar] [CrossRef] [PubMed]
  52. Matteis, M.; Polverino, F.; Spaziano, G.; Roviezzo, F.; Santoriello, C.; Sullo, N.; Bucci, M.R.; Rossi, F.; Polverino, M.; Owen, C.A.; et al. Effects of Sex Hormones on Bronchial Reactivity during the Menstrual Cycle. BMC Pulm. Med. 2014, 14, 108. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Pace, S.; Werz, O. Impact of Androgens on Inflammation-Related Lipid Mediator Biosynthesis in Innate Immune Cells. Front. Immunol. 2020, 11, 1356. [Google Scholar] [CrossRef] [PubMed]
  54. Roviezzo, F.; Sorrentino, R.; Iacono, V.M.; Brancaleone, V.; Terlizzi, M.; Riemma, M.A.; Bertolino, A.; Rossi, A.; Matteis, M.; Spaziano, G.; et al. Disodium Cromoglycate Inhibits Asthma-like Features Induced by Sphingosine-1-Phosphate. Pharmacol. Res. 2016, 113, 626–635. [Google Scholar] [CrossRef]
  55. Rossi, A.; Pergola, C.; Pace, S.; Rådmark, O.; Werz, O.; Sautebin, L. In Vivo Sex Differences in Leukotriene Biosynthesis in Zymosan-Induced Peritonitis. Pharmacol. Res. 2014, 87, 1–7. [Google Scholar] [CrossRef]
  56. Pace, S.; Pergola, C.; Dehm, F.; Rossi, A.; Gerstmeier, J.; Troisi, F.; Pein, H.; Schaible, A.M.; Weinigel, C.; Rummler, S.; et al. Androgen-Mediated Sex Bias Impairs Efficiency of Leukotriene Biosynthesis Inhibitors in Males. J. Clin. Investig. 2017, 127, 3167–3176. [Google Scholar] [CrossRef] [Green Version]
  57. Shepherd, R.; Cheung, A.S.; Pang, K.; Saffery, R.; Novakovic, B. Sexual Dimorphism in Innate Immunity: The Role of Sex Hormones and Epigenetics. Front. Immunol. 2021, 11, 604000. [Google Scholar] [CrossRef]
  58. Pergola, C.; Rogge, A.; Dodt, G.; Northoff, H.; Weinigel, C.; Barz, D.; Rådmark, O.; Sautebin, L.; Werz, O. Testosterone Suppresses Phospholipase D, Causing Sex Differences in Leukotriene Biosynthesis in Human Monocytes. FASEB J. 2011, 25, 3377–3387. [Google Scholar] [CrossRef]
  59. Volf, N.V.; Belousova, L.V.; Knyazev, G.G.; Kulikov, A.V. Gender Differences in Association between Serotonin Transporter Gene Polymorphism and Resting-State EEG Activity. Neuroscience 2015, 284, 513–521. [Google Scholar] [CrossRef]
  60. Bi, D.; Chen, M.; Zhang, X.; Wang, H.; Xia, L.; Shang, Q.; Li, T.; Zhu, D.; Blomgren, K.; He, L.; et al. The Association between Sex-Related Interleukin-6 Gene Polymorphisms and the Risk for Cerebral Palsy. J. Neuroinflamm. 2014, 11, 100. [Google Scholar] [CrossRef] [Green Version]
Jcm 12 02775 g001 550
Figure 1. (A) Median 5-LO serum levels in M (blue) and W (pink) according to genotype ALOX5 rs2029253 polymorphism. Biological replicate: 4 M (2 healthy and 2 atopic) and 4 W (2 healthy and 2 atopic) without mutation; 4 M (all healthy) and 6 W (3 healthy and 3 atopic) carrying homozygous wild-type allele; 3 M (all healthy) and 4 W (3 healthy and 1 atopic) carrying homozygous variant allele; 6 M (3 healthy and 3 atopic) and 4 W (2 healthy and 2 atopic) carrying heterozygous alleles. (B) Median 5-LO serum levels in M (blue) and W (pink) according to genotype ALOX5 rs2115819 polymorphism. Biological replicate: 4 M (2 healthy and 2 atopic) and 4 W (2 healthy and 2 atopic) without mutation; 6 M (all healthy) and 8 W (4 healthy and 4 atopic) carrying homozygous wild-type allele; 6 M (all healthy) and 6 W (2 healthy and 4 atopic) carrying homozygous variant allele; 7 M (4 healthy and 3 atopic) 6 W (3 healthy and 3 atopic) carrying heterozygous alleles. All samples were run in duplicate and results were shown as means ± SEM. The statistical tests used in these analyses were the one-way analysis of variance followed by the Tukey Multiple Comparison Test. * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 1. (A) Median 5-LO serum levels in M (blue) and W (pink) according to genotype ALOX5 rs2029253 polymorphism. Biological replicate: 4 M (2 healthy and 2 atopic) and 4 W (2 healthy and 2 atopic) without mutation; 4 M (all healthy) and 6 W (3 healthy and 3 atopic) carrying homozygous wild-type allele; 3 M (all healthy) and 4 W (3 healthy and 1 atopic) carrying homozygous variant allele; 6 M (3 healthy and 3 atopic) and 4 W (2 healthy and 2 atopic) carrying heterozygous alleles. (B) Median 5-LO serum levels in M (blue) and W (pink) according to genotype ALOX5 rs2115819 polymorphism. Biological replicate: 4 M (2 healthy and 2 atopic) and 4 W (2 healthy and 2 atopic) without mutation; 6 M (all healthy) and 8 W (4 healthy and 4 atopic) carrying homozygous wild-type allele; 6 M (all healthy) and 6 W (2 healthy and 4 atopic) carrying homozygous variant allele; 7 M (4 healthy and 3 atopic) 6 W (3 healthy and 3 atopic) carrying heterozygous alleles. All samples were run in duplicate and results were shown as means ± SEM. The statistical tests used in these analyses were the one-way analysis of variance followed by the Tukey Multiple Comparison Test. * p < 0.05, ** p < 0.01, *** p < 0.001.
Jcm 12 02775 g001
Jcm 12 02775 g002 550
Figure 2. (A) Median LTB4 serum levels in M (blue) and W (pink) according to genotype ALOX5 rs2029253 polymorphism. Biological replicate: 4 M (2 healthy and 2 atopic) and 4 W (2 healthy and 2 atopic) without mutation; 4 M (all healthy) and 6 W (3 healthy and 3 atopic) carrying homozygous wild-type allele; 3 M (all healthy) and 4 W (3 healthy and 1 atopic) carrying homozygous variant allele; 6 M (3 healthy and 3 atopic) and 4 W (2 healthy and 2 atopic) carrying heterozygous alleles. (B) Median 5-LO serum levels in M (blue) and W (pink) according to genotype ALOX5 rs2115819 polymorphism. Biological replicate: 4 M (2 healthy and 2 atopic) and 4 W (2 healthy and 2 atopic) without mutation; 6 M (all healthy) and 8 W (4 healthy and 4 atopic) carrying homozygous wild-type allele; 6 M (all healthy) and 6 W (2 healthy and 4 atopic) carrying homozygous variant allele; 7 M (4 healthy and 3 atopic) 6 W (3 healthy and 3 atopic) carrying heterozygous alleles. All samples were run in duplicate and results were shown as means ± SEM. The statistical tests used in these analyses were the one-way analysis of variance followed by the Tukey Multiple Comparison Test. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Figure 2. (A) Median LTB4 serum levels in M (blue) and W (pink) according to genotype ALOX5 rs2029253 polymorphism. Biological replicate: 4 M (2 healthy and 2 atopic) and 4 W (2 healthy and 2 atopic) without mutation; 4 M (all healthy) and 6 W (3 healthy and 3 atopic) carrying homozygous wild-type allele; 3 M (all healthy) and 4 W (3 healthy and 1 atopic) carrying homozygous variant allele; 6 M (3 healthy and 3 atopic) and 4 W (2 healthy and 2 atopic) carrying heterozygous alleles. (B) Median 5-LO serum levels in M (blue) and W (pink) according to genotype ALOX5 rs2115819 polymorphism. Biological replicate: 4 M (2 healthy and 2 atopic) and 4 W (2 healthy and 2 atopic) without mutation; 6 M (all healthy) and 8 W (4 healthy and 4 atopic) carrying homozygous wild-type allele; 6 M (all healthy) and 6 W (2 healthy and 4 atopic) carrying homozygous variant allele; 7 M (4 healthy and 3 atopic) 6 W (3 healthy and 3 atopic) carrying heterozygous alleles. All samples were run in duplicate and results were shown as means ± SEM. The statistical tests used in these analyses were the one-way analysis of variance followed by the Tukey Multiple Comparison Test. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Jcm 12 02775 g002
Jcm 12 02775 g003 550
Figure 3. Correlation between LTB4 and 5-LO serum levels according to genotype ALOX5 rs2029253 polymorphism in M (A) and W (B). Results were shown as means ± SEM. The statistical test used in these analyses was the Pearson correlation test considering 95% confidence interval.
Figure 3. Correlation between LTB4 and 5-LO serum levels according to genotype ALOX5 rs2029253 polymorphism in M (A) and W (B). Results were shown as means ± SEM. The statistical test used in these analyses was the Pearson correlation test considering 95% confidence interval.
Jcm 12 02775 g003
Jcm 12 02775 g004 550
Figure 4. Correlation between LTB4 and 5-LO serum levels according to genotype ALOX5 rs2115819 polymorphism in M (A) and W (B). Results were shown as means ± SEM. The statistical test used in these analyses was the Pearson correlation test considering 95% confidence interval.
Figure 4. Correlation between LTB4 and 5-LO serum levels according to genotype ALOX5 rs2115819 polymorphism in M (A) and W (B). Results were shown as means ± SEM. The statistical test used in these analyses was the Pearson correlation test considering 95% confidence interval.
Jcm 12 02775 g004
Table
Table 1. Demographic characteristics and pharmacological treatments of enrolled subjects. Results were shown as means ± SD. The statistical tests used in these analyses were the one-way analysis of variance followed by the Tukey Multiple Comparison Test. NS = not significant.
Table 1. Demographic characteristics and pharmacological treatments of enrolled subjects. Results were shown as means ± SD. The statistical tests used in these analyses were the one-way analysis of variance followed by the Tukey Multiple Comparison Test. NS = not significant.
AtopicHealthyp Value
Total participants (N)36114
Mean Age (SD)39.3(21.8)59.6(24.5)NS
Gender (M/F) (N)18/1856/58NS
Ethnicity
Caucasian36114NS
BMI (SD)23.2(3.9)24.5(1.2)NS
Smoking habit (current/former smoker) (N)8/315/7<0.05
Comorbidities
- Hypertension (%) N5 (13.9%)16(14%)NS
- Diabetes N (%)1 (2.8%)0NS
- Other cardiovascular diseases (%)3 (8.3%)0<0.0001
Medications
- Corticosteroids (%) N14 (38.9%)21(18.4%)<0.0001
- B-blocked (%) N2 (5.5%)5(4.4%)NS
- Ca antagonists (%) N3 (8.3%)2(1.7%)<0.0001
<0.0001
- Antihistamines (%) N9(25%)1(0.9%)<0.0001
Table
Table 2. Frequency of mutation in atopic and healthy M and W according to genotype ALOX5 rs2029253 polymorphism. The statistical tests used in these analyses were the one-way analysis of variance followed by the Tukey Multiple Comparison Test.
Table 2. Frequency of mutation in atopic and healthy M and W according to genotype ALOX5 rs2029253 polymorphism. The statistical tests used in these analyses were the one-way analysis of variance followed by the Tukey Multiple Comparison Test.
rs2029253
ALOX5		MenWomenp Value
Tot. with mutation28/74 (37.9%)34/76 (44.7%)<0.01
Atopic with mutation6/17 (35.3%)8/19 (42.1%)<0.05
Healthy with mutation22/57 (38.6%)26/57 (45.6%)0.01
Table
Table 3. Frequency of mutation in atopic and healthy M and W according to genotype ALOX5 rs2115819 polymorphism. The statistical tests used in these analyses were the one-way analysis of variance followed by the Tukey Multiple Comparison Test.
Table 3. Frequency of mutation in atopic and healthy M and W according to genotype ALOX5 rs2115819 polymorphism. The statistical tests used in these analyses were the one-way analysis of variance followed by the Tukey Multiple Comparison Test.
rs2115819
ALOX5		MenWomenp Value
Tot. with mutation34/74 (45.9%)35/76 (46.1%)NS
Atopic with mutation6/17 (35.3%)13/19 (68.4%)<0.0001
Healthy with mutation28/57 (49.1%)22/57 (38.6%)<0.001
Table
Table 4. Genotype and allele frequency in Healthy (A) and Atopic (B) M and W, based on the ALOX5 rs2029253 polymorphism. The statistical tests used in these analyses were the one-way analysis of variance followed by the Tukey Multiple Comparison Test.
Table 4. Genotype and allele frequency in Healthy (A) and Atopic (B) M and W, based on the ALOX5 rs2029253 polymorphism. The statistical tests used in these analyses were the one-way analysis of variance followed by the Tukey Multiple Comparison Test.
A
rs2029253
ALOX5		Healthy MenHealthy Womenp  Value
Without mutation35/57 (61.4%)31/57 (54.4%)<0.001
Homozygous wild-type7/57 (12.3%)11/57 (19.3%)<0.001
Homozygous variant10/57 (17.5%)4/57 (7%)<0.0001
Heterozygous5/57 (8.8%)11/57 (19.3%)<0.0001
B
rs2029253
ALOX5		Atopic MenAtopic Womenp  Value
Without mutation11/17 (64.7%)11/19 (57.9%)<0.001
Homozygous wild-type0/17 (0%)4/19 (21.05%)<0.0001
Homozygous variant0/17 (0%)1/19 (5.3%)<0.0001
Heterozygous6/17 (35.3%) 3/19 (15.8%)<0.0001
Table
Table 5. Genotype and allele frequency in Healthy (A) and Atopic (B) M and W, based on the ALOX5 rs2115819 polymorphism. The statistical tests used in these analyses were the one-way analysis of variance followed by the Tukey Multiple Comparison Test.
Table 5. Genotype and allele frequency in Healthy (A) and Atopic (B) M and W, based on the ALOX5 rs2115819 polymorphism. The statistical tests used in these analyses were the one-way analysis of variance followed by the Tukey Multiple Comparison Test.
A
rs2115819
ALOX5		Healthy MenHealthy Womenp  Value
Without mutation29/57 (50.8%)35/57 (61.4%)<0.0001
Homozygous wild-type9/57 (15.8%)6/57 (10.5%)<0.001
Homozygous variant11/57 (19.3%)2/57 (3.5%)<0.0001
Heterozygous8/57 (14.1%)14/57 (24.6%)<0.0001
B
rs2115819
ALOX5		Atopic MenAtopic Womenp  Value
Without mutation11/17 (64.7%)6/19 (31.6%)<0.0001
Homozygous wild-type0/17 (0%)4/19 (21.05%)<0.0001
Homozygous variant0/17 (0%)4/19 (21.05%)<0.0001
Heterozygous6/17 (35.3%) 5/19 (26.3%)<0.0001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Mirra, D.; Esposito, R.; Spaziano, G.; Rafaniello, C.; Iovino, P.; Cione, E.; Gallelli, L.; D’Agostino, B. Association between Sex-Related ALOX5 Gene Polymorphisms and Lung Atopy Risk. J. Clin. Med. 2023, 12, 2775. https://doi.org/10.3390/jcm12082775

AMA Style

Mirra D, Esposito R, Spaziano G, Rafaniello C, Iovino P, Cione E, Gallelli L, D’Agostino B. Association between Sex-Related ALOX5 Gene Polymorphisms and Lung Atopy Risk. Journal of Clinical Medicine. 2023; 12(8):2775. https://doi.org/10.3390/jcm12082775

Chicago/Turabian Style

Mirra, Davida, Renata Esposito, Giuseppe Spaziano, Concetta Rafaniello, Pasquale Iovino, Erika Cione, Luca Gallelli, and Bruno D’Agostino. 2023. "Association between Sex-Related ALOX5 Gene Polymorphisms and Lung Atopy Risk" Journal of Clinical Medicine 12, no. 8: 2775. https://doi.org/10.3390/jcm12082775

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop